Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure
People with hepatitis C virus (HCV) infection who have failed treatment with an all‐oral regimen represent a challenging treatment population. The present studies evaluated the safety and efficacy of grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, in participants who had failed a...
Gespeichert in:
| Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2017-12, Vol.66 (6), p.1794-1804 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1804 |
|---|---|
| container_issue | 6 |
| container_start_page | 1794 |
| container_title | Hepatology (Baltimore, Md.) |
| container_volume | 66 |
| creator | Wyles, David Wedemeyer, Heiner Ben‐Ari, Ziv Gane, Edward J. Hansen, Jesper Bach Jacobson, Ira M. Laursen, Alex L. Luetkemeyer, Annie Nahass, Ronald Pianko, Stephen Zeuzem, Stefan Jumes, Patricia Huang, Hsueh‐Cheng Butterton, Joan Robertson, Michael Wahl, Janice Barr, Eliav Joeng, Hee‐Koung Martin, Elizabeth Serfaty, Lawrence |
| description | People with hepatitis C virus (HCV) infection who have failed treatment with an all‐oral regimen represent a challenging treatment population. The present studies evaluated the safety and efficacy of grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, in participants who had failed an NS5A inhibitor‐containing regimen. C‐SURGE (PN‐3682‐021) and C‐CREST Part C (PN‐3682‐011 and ‐012) were open‐label, multicenter studies. Participants who had previously relapsed following an NS5A inhibitor–containing all‐oral regimen were retreated with grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg alone for 24 weeks or with ribavirin for 16 weeks. The primary efficacy endpoint was sustained virologic response (HCV RNA below the limit of quantitation [ |
| doi_str_mv | 10.1002/hep.29358 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1917360448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1966197865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3888-871626b36a75336a21fabf87903f97beea1081564e117cc36f0bf41e37b6076d3</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMoWqsH_4AEvCi4bT5283GUolUoKqgXL0t2O8Et-1GTjVJ_vbFVD4KXmWF4eGd4EDqiZEQJYeMXWI6Y5pnaQgOaMZlwnpFtNCBMkkRTrvfQvvcLQohOmdpFe0wJpSjTA_Q8deajWzp4q9w5duHD-PVk2jkOS1fZzhchbrDtHI53TF_1lccTHHfBY2N7cPj2IbvAvQPTN9D22JqqDg4O0I41tYfD7z5ET1eXj5PrZHY3vZlczJKSK6USJalgouDCyIzHyqg1hVVSE261LAAMJYpmIgVKZVlyYUlhUwpcFoJIMedDdLrJXbruNYDv86byJdS1aaELPqeaSi5ImqqInvxBF11wbfwuUkJQLZXIInW2oUrXee_A5lFEY9wqpyT_Ep5HEflaeGSPvxND0cD8l_wxHIHxBnivalj9n5RfX95vIj8BeTKJAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1966197865</pqid></control><display><type>article</type><title>Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Wyles, David ; Wedemeyer, Heiner ; Ben‐Ari, Ziv ; Gane, Edward J. ; Hansen, Jesper Bach ; Jacobson, Ira M. ; Laursen, Alex L. ; Luetkemeyer, Annie ; Nahass, Ronald ; Pianko, Stephen ; Zeuzem, Stefan ; Jumes, Patricia ; Huang, Hsueh‐Cheng ; Butterton, Joan ; Robertson, Michael ; Wahl, Janice ; Barr, Eliav ; Joeng, Hee‐Koung ; Martin, Elizabeth ; Serfaty, Lawrence</creator><creatorcontrib>Wyles, David ; Wedemeyer, Heiner ; Ben‐Ari, Ziv ; Gane, Edward J. ; Hansen, Jesper Bach ; Jacobson, Ira M. ; Laursen, Alex L. ; Luetkemeyer, Annie ; Nahass, Ronald ; Pianko, Stephen ; Zeuzem, Stefan ; Jumes, Patricia ; Huang, Hsueh‐Cheng ; Butterton, Joan ; Robertson, Michael ; Wahl, Janice ; Barr, Eliav ; Joeng, Hee‐Koung ; Martin, Elizabeth ; Serfaty, Lawrence ; C-CREST Part C and C-SURGE Investigators ; for the C‐CREST Part C and C‐SURGE Investigators</creatorcontrib><description>People with hepatitis C virus (HCV) infection who have failed treatment with an all‐oral regimen represent a challenging treatment population. The present studies evaluated the safety and efficacy of grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, in participants who had failed an NS5A inhibitor‐containing regimen. C‐SURGE (PN‐3682‐021) and C‐CREST Part C (PN‐3682‐011 and ‐012) were open‐label, multicenter studies. Participants who had previously relapsed following an NS5A inhibitor–containing all‐oral regimen were retreated with grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg alone for 24 weeks or with ribavirin for 16 weeks. The primary efficacy endpoint was sustained virologic response (HCV RNA below the limit of quantitation [<15 IU/mL]) 12 weeks after treatment completion (SVR12). In C‐SURGE, SVR12 was achieved by 49/49 (100%) and 43/44 (98%) genotype (GT)1 participants in the 24‐week no ribavirin arm and the 16‐week plus ribavirin arm (lost to follow‐up, n = 1), respectively. In C‐CREST Part C, SVR12 was achieved by 23/24 (96%) participants treated for 16 weeks with ribavirin (GT1, 2/2 [100%]; GT2, 13/14 [93%]; GT3, 8/8 [100%]). One participant with GT2 infection discontinued study medication after a single dose of grazoprevir, ruzasvir, and uprifosbuvir plus ribavirin due to serious adverse events of vomiting and tachycardia. The presence of baseline resistance‐associated substitutions had no impact on SVR12. No participant who completed treatment in either study experienced virologic failure. Conclusion: Grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, for 16 or 24 weeks was safe and highly effective in participants with HCV infection who had previously failed NS5A inhibitor–containing therapy. (Hepatology 2017;66:1794–1804)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.29358</identifier><identifier>PMID: 28688129</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>Adult ; Aged ; Antiretroviral drugs ; Antiviral Agents - therapeutic use ; Drug Therapy, Combination ; Female ; Hepatitis ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatology ; Humans ; Infections ; Interferon ; Male ; Middle Aged ; Population studies ; Quantitation ; Ribavirin ; Ribonucleic acid ; RNA ; Tachycardia ; Treatment Failure ; Treatment Outcome ; Vomiting</subject><ispartof>Hepatology (Baltimore, Md.), 2017-12, Vol.66 (6), p.1794-1804</ispartof><rights>2017 by the American Association for the Study of Liver Diseases.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3888-871626b36a75336a21fabf87903f97beea1081564e117cc36f0bf41e37b6076d3</citedby><cites>FETCH-LOGICAL-c3888-871626b36a75336a21fabf87903f97beea1081564e117cc36f0bf41e37b6076d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.29358$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.29358$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28688129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wyles, David</creatorcontrib><creatorcontrib>Wedemeyer, Heiner</creatorcontrib><creatorcontrib>Ben‐Ari, Ziv</creatorcontrib><creatorcontrib>Gane, Edward J.</creatorcontrib><creatorcontrib>Hansen, Jesper Bach</creatorcontrib><creatorcontrib>Jacobson, Ira M.</creatorcontrib><creatorcontrib>Laursen, Alex L.</creatorcontrib><creatorcontrib>Luetkemeyer, Annie</creatorcontrib><creatorcontrib>Nahass, Ronald</creatorcontrib><creatorcontrib>Pianko, Stephen</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Jumes, Patricia</creatorcontrib><creatorcontrib>Huang, Hsueh‐Cheng</creatorcontrib><creatorcontrib>Butterton, Joan</creatorcontrib><creatorcontrib>Robertson, Michael</creatorcontrib><creatorcontrib>Wahl, Janice</creatorcontrib><creatorcontrib>Barr, Eliav</creatorcontrib><creatorcontrib>Joeng, Hee‐Koung</creatorcontrib><creatorcontrib>Martin, Elizabeth</creatorcontrib><creatorcontrib>Serfaty, Lawrence</creatorcontrib><creatorcontrib>C-CREST Part C and C-SURGE Investigators</creatorcontrib><creatorcontrib>for the C‐CREST Part C and C‐SURGE Investigators</creatorcontrib><title>Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>People with hepatitis C virus (HCV) infection who have failed treatment with an all‐oral regimen represent a challenging treatment population. The present studies evaluated the safety and efficacy of grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, in participants who had failed an NS5A inhibitor‐containing regimen. C‐SURGE (PN‐3682‐021) and C‐CREST Part C (PN‐3682‐011 and ‐012) were open‐label, multicenter studies. Participants who had previously relapsed following an NS5A inhibitor–containing all‐oral regimen were retreated with grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg alone for 24 weeks or with ribavirin for 16 weeks. The primary efficacy endpoint was sustained virologic response (HCV RNA below the limit of quantitation [<15 IU/mL]) 12 weeks after treatment completion (SVR12). In C‐SURGE, SVR12 was achieved by 49/49 (100%) and 43/44 (98%) genotype (GT)1 participants in the 24‐week no ribavirin arm and the 16‐week plus ribavirin arm (lost to follow‐up, n = 1), respectively. In C‐CREST Part C, SVR12 was achieved by 23/24 (96%) participants treated for 16 weeks with ribavirin (GT1, 2/2 [100%]; GT2, 13/14 [93%]; GT3, 8/8 [100%]). One participant with GT2 infection discontinued study medication after a single dose of grazoprevir, ruzasvir, and uprifosbuvir plus ribavirin due to serious adverse events of vomiting and tachycardia. The presence of baseline resistance‐associated substitutions had no impact on SVR12. No participant who completed treatment in either study experienced virologic failure. Conclusion: Grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, for 16 or 24 weeks was safe and highly effective in participants with HCV infection who had previously failed NS5A inhibitor–containing therapy. (Hepatology 2017;66:1794–1804)</description><subject>Adult</subject><subject>Aged</subject><subject>Antiretroviral drugs</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Infections</subject><subject>Interferon</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Population studies</subject><subject>Quantitation</subject><subject>Ribavirin</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Tachycardia</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><subject>Vomiting</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LAzEQhoMoWqsH_4AEvCi4bT5283GUolUoKqgXL0t2O8Et-1GTjVJ_vbFVD4KXmWF4eGd4EDqiZEQJYeMXWI6Y5pnaQgOaMZlwnpFtNCBMkkRTrvfQvvcLQohOmdpFe0wJpSjTA_Q8deajWzp4q9w5duHD-PVk2jkOS1fZzhchbrDtHI53TF_1lccTHHfBY2N7cPj2IbvAvQPTN9D22JqqDg4O0I41tYfD7z5ET1eXj5PrZHY3vZlczJKSK6USJalgouDCyIzHyqg1hVVSE261LAAMJYpmIgVKZVlyYUlhUwpcFoJIMedDdLrJXbruNYDv86byJdS1aaELPqeaSi5ImqqInvxBF11wbfwuUkJQLZXIInW2oUrXee_A5lFEY9wqpyT_Ep5HEflaeGSPvxND0cD8l_wxHIHxBnivalj9n5RfX95vIj8BeTKJAA</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Wyles, David</creator><creator>Wedemeyer, Heiner</creator><creator>Ben‐Ari, Ziv</creator><creator>Gane, Edward J.</creator><creator>Hansen, Jesper Bach</creator><creator>Jacobson, Ira M.</creator><creator>Laursen, Alex L.</creator><creator>Luetkemeyer, Annie</creator><creator>Nahass, Ronald</creator><creator>Pianko, Stephen</creator><creator>Zeuzem, Stefan</creator><creator>Jumes, Patricia</creator><creator>Huang, Hsueh‐Cheng</creator><creator>Butterton, Joan</creator><creator>Robertson, Michael</creator><creator>Wahl, Janice</creator><creator>Barr, Eliav</creator><creator>Joeng, Hee‐Koung</creator><creator>Martin, Elizabeth</creator><creator>Serfaty, Lawrence</creator><general>Wolters Kluwer Health, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201712</creationdate><title>Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure</title><author>Wyles, David ; Wedemeyer, Heiner ; Ben‐Ari, Ziv ; Gane, Edward J. ; Hansen, Jesper Bach ; Jacobson, Ira M. ; Laursen, Alex L. ; Luetkemeyer, Annie ; Nahass, Ronald ; Pianko, Stephen ; Zeuzem, Stefan ; Jumes, Patricia ; Huang, Hsueh‐Cheng ; Butterton, Joan ; Robertson, Michael ; Wahl, Janice ; Barr, Eliav ; Joeng, Hee‐Koung ; Martin, Elizabeth ; Serfaty, Lawrence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3888-871626b36a75336a21fabf87903f97beea1081564e117cc36f0bf41e37b6076d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiretroviral drugs</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Infections</topic><topic>Interferon</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Population studies</topic><topic>Quantitation</topic><topic>Ribavirin</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Tachycardia</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wyles, David</creatorcontrib><creatorcontrib>Wedemeyer, Heiner</creatorcontrib><creatorcontrib>Ben‐Ari, Ziv</creatorcontrib><creatorcontrib>Gane, Edward J.</creatorcontrib><creatorcontrib>Hansen, Jesper Bach</creatorcontrib><creatorcontrib>Jacobson, Ira M.</creatorcontrib><creatorcontrib>Laursen, Alex L.</creatorcontrib><creatorcontrib>Luetkemeyer, Annie</creatorcontrib><creatorcontrib>Nahass, Ronald</creatorcontrib><creatorcontrib>Pianko, Stephen</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Jumes, Patricia</creatorcontrib><creatorcontrib>Huang, Hsueh‐Cheng</creatorcontrib><creatorcontrib>Butterton, Joan</creatorcontrib><creatorcontrib>Robertson, Michael</creatorcontrib><creatorcontrib>Wahl, Janice</creatorcontrib><creatorcontrib>Barr, Eliav</creatorcontrib><creatorcontrib>Joeng, Hee‐Koung</creatorcontrib><creatorcontrib>Martin, Elizabeth</creatorcontrib><creatorcontrib>Serfaty, Lawrence</creatorcontrib><creatorcontrib>C-CREST Part C and C-SURGE Investigators</creatorcontrib><creatorcontrib>for the C‐CREST Part C and C‐SURGE Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wyles, David</au><au>Wedemeyer, Heiner</au><au>Ben‐Ari, Ziv</au><au>Gane, Edward J.</au><au>Hansen, Jesper Bach</au><au>Jacobson, Ira M.</au><au>Laursen, Alex L.</au><au>Luetkemeyer, Annie</au><au>Nahass, Ronald</au><au>Pianko, Stephen</au><au>Zeuzem, Stefan</au><au>Jumes, Patricia</au><au>Huang, Hsueh‐Cheng</au><au>Butterton, Joan</au><au>Robertson, Michael</au><au>Wahl, Janice</au><au>Barr, Eliav</au><au>Joeng, Hee‐Koung</au><au>Martin, Elizabeth</au><au>Serfaty, Lawrence</au><aucorp>C-CREST Part C and C-SURGE Investigators</aucorp><aucorp>for the C‐CREST Part C and C‐SURGE Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2017-12</date><risdate>2017</risdate><volume>66</volume><issue>6</issue><spage>1794</spage><epage>1804</epage><pages>1794-1804</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><abstract>People with hepatitis C virus (HCV) infection who have failed treatment with an all‐oral regimen represent a challenging treatment population. The present studies evaluated the safety and efficacy of grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, in participants who had failed an NS5A inhibitor‐containing regimen. C‐SURGE (PN‐3682‐021) and C‐CREST Part C (PN‐3682‐011 and ‐012) were open‐label, multicenter studies. Participants who had previously relapsed following an NS5A inhibitor–containing all‐oral regimen were retreated with grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg alone for 24 weeks or with ribavirin for 16 weeks. The primary efficacy endpoint was sustained virologic response (HCV RNA below the limit of quantitation [<15 IU/mL]) 12 weeks after treatment completion (SVR12). In C‐SURGE, SVR12 was achieved by 49/49 (100%) and 43/44 (98%) genotype (GT)1 participants in the 24‐week no ribavirin arm and the 16‐week plus ribavirin arm (lost to follow‐up, n = 1), respectively. In C‐CREST Part C, SVR12 was achieved by 23/24 (96%) participants treated for 16 weeks with ribavirin (GT1, 2/2 [100%]; GT2, 13/14 [93%]; GT3, 8/8 [100%]). One participant with GT2 infection discontinued study medication after a single dose of grazoprevir, ruzasvir, and uprifosbuvir plus ribavirin due to serious adverse events of vomiting and tachycardia. The presence of baseline resistance‐associated substitutions had no impact on SVR12. No participant who completed treatment in either study experienced virologic failure. Conclusion: Grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, for 16 or 24 weeks was safe and highly effective in participants with HCV infection who had previously failed NS5A inhibitor–containing therapy. (Hepatology 2017;66:1794–1804)</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>28688129</pmid><doi>10.1002/hep.29358</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-9139 |
| ispartof | Hepatology (Baltimore, Md.), 2017-12, Vol.66 (6), p.1794-1804 |
| issn | 0270-9139 1527-3350 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1917360448 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Antiretroviral drugs Antiviral Agents - therapeutic use Drug Therapy, Combination Female Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatology Humans Infections Interferon Male Middle Aged Population studies Quantitation Ribavirin Ribonucleic acid RNA Tachycardia Treatment Failure Treatment Outcome Vomiting |
| title | Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T01%3A31%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Grazoprevir,%20ruzasvir,%20and%20uprifosbuvir%20for%20hepatitis%20C%20virus%20after%20NS5A%20treatment%20failure&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Wyles,%20David&rft.aucorp=C-CREST%20Part%20C%20and%20C-SURGE%20Investigators&rft.date=2017-12&rft.volume=66&rft.issue=6&rft.spage=1794&rft.epage=1804&rft.pages=1794-1804&rft.issn=0270-9139&rft.eissn=1527-3350&rft_id=info:doi/10.1002/hep.29358&rft_dat=%3Cproquest_cross%3E1966197865%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1966197865&rft_id=info:pmid/28688129&rfr_iscdi=true |